Discontinued — last reported Q4 '25
Insmed Proceeds from maturities of marketable securities decreased by 34.9% to $284.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 60.6%, from $721.00M to $284.00M. Over 2 years (FY 2023 to FY 2025), Proceeds from maturities of marketable securities shows an upward trend with a 136.1% CAGR.
High proceeds indicate a liquidation of investment assets, often to fund operations, acquisitions, or debt repayment.
This metric tracks the cash inflows from the sale or maturity of short-term investments and marketable securities. It re...
Standard for all companies with treasury management functions; indicates the level of liquid investment activity.
other_proceeds_from_sale_and_maturity_of_marketable_securities| Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $45.00M | $20.00M | $10.00M | $300.00M | $300.00M | $0.00 | $0.00 | $716.00M | $721.00M | $508.00M | $425.00M | $436.00M | $284.00M |
| QoQ Change | — | — | — | -55.6% | -50.0% | >999% | +0.0% | -100.0% | — | — | +0.7% | -29.5% | -16.3% | +2.6% | -34.9% |
| YoY Change | — | — | — | — | — | — | +566.7% | -100.0% | -100.0% | +138.7% | +140.3% | — | — | -39.1% | -60.6% |